CLL, or chronic lymphocytic leukemia, is a slow-growing cancer of the blood and bone marrow that affects a type of white blood cell called B lymphocytes. It is the most common form of adult leukemia in the Western world, with an estimated 23,690 new cases expected in the United States in 2025. The median age at diagnosis is 70, and up to 80% of people have no symptoms when the disease is first detected, often discovered through routine blood work.
How CLL Develops
In a healthy immune system, B lymphocytes help fight infections by producing antibodies. In CLL, a single abnormal B cell begins to copy itself uncontrollably, producing a growing population of identical, dysfunctional cells. These cancerous lymphocytes accumulate in the blood, bone marrow, lymph nodes, spleen, and liver over time. Unlike aggressive leukemias where abnormal cells multiply rapidly, CLL cells build up gradually because they survive far longer than normal B cells rather than dividing at an unusually fast rate.
The cancerous cells rely on chemical signals from surrounding tissue to survive. Cells in the bone marrow and lymph nodes release signaling molecules that attract CLL cells and help keep them alive. This is why CLL tends to concentrate in these locations and why treatments that interrupt those survival signals have become central to managing the disease.
CLL and a related condition called small lymphocytic lymphoma (SLL) are considered the same disease. The difference is where the cancer cells primarily collect: in CLL, they’re found mostly in the blood and bone marrow, while in SLL, they accumulate mainly in the lymph nodes.
Common Symptoms
Most people with CLL feel completely fine when they’re diagnosed. The disease is frequently caught when a routine blood test reveals an unexpectedly high white blood cell count. When symptoms do appear, they tend to develop slowly over months or years.
Enlarged lymph nodes are the most common sign in people who have symptoms. You might notice painless swelling in the neck, armpits, or groin. An enlarged spleen can cause a feeling of fullness or discomfort in the upper left abdomen and early satiety (feeling full after eating very little). Fatigue and tiredness often develop as the disease progresses, sometimes related to anemia. About 10% of people with CLL develop a specific type of anemia where the immune system mistakenly destroys its own red blood cells.
As CLL advances, some people experience what doctors call “B symptoms”: unexplained weight loss of more than 10% of body weight over six months, fevers, drenching night sweats, and severe fatigue that interferes with daily life. Repeated infections like pneumonia and shingles can also occur because the abnormal lymphocytes crowd out healthy immune cells. In some cases, low platelet counts lead to easy bruising or tiny red spots on the skin called petechiae.
How CLL Is Diagnosed
Diagnosis requires a sustained count of at least 5,000 B lymphocytes per microliter of blood, maintained for at least three months. A simple blood draw can identify these cells, but confirming CLL requires a specialized lab test called flow cytometry, which examines the surface of each cell for a specific combination of protein markers. CLL cells carry a distinctive pattern: they display the marker CD5 (normally found on a different type of immune cell) alongside typical B cell markers like CD19, CD20, and CD23. This unusual combination is what distinguishes CLL from other blood cancers.
Staging and What It Means
Once diagnosed, CLL is assigned a stage that reflects how far the disease has progressed. Two staging systems are used, depending on where you’re being treated. In the United States, the Rai system is more common. It works on a straightforward principle: CLL starts in the blood and marrow, then spreads to the lymph nodes, spleen, and liver, and eventually impairs the bone marrow’s ability to produce normal blood cells.
- Early stage (Rai 0): The only finding is a high lymphocyte count in the blood and bone marrow, with no enlarged organs or low blood counts.
- Intermediate stages (Rai I–II): Lymph nodes, spleen, or liver have become enlarged.
- Advanced stages (Rai III–IV): The bone marrow is significantly affected, leading to anemia or low platelet counts.
The Binet system, more widely used in Europe, takes a similar approach. It divides patients into three groups (A, B, and C) based on how many areas of the body show enlarged lymph nodes or organs, and whether anemia or low platelets have developed. Both systems help guide decisions about whether treatment is needed now or can wait.
Genetic Factors That Shape the Outlook
Not all CLL behaves the same way, and genetic testing plays a major role in predicting how the disease will progress. Two factors stand out.
The first is a gene called IGHV, which relates to how mature the cancerous B cells were before they became cancerous. If the IGHV gene shows signs of mutation (meaning the B cell had already gone through a normal maturation process), the disease generally progresses more slowly and responds better to treatment. If IGHV is unmutated, the CLL tends to be more aggressive, with higher rates of disease progression even after successful initial treatment.
The second major factor involves a gene called TP53, which normally acts as a brake on cancer growth. When TP53 is missing or damaged, CLL cells lose a critical safeguard against uncontrolled growth. About 90% of patients who are missing a specific piece of chromosome 17 (where TP53 lives) also carry a TP53 mutation, but the mutation can occur on its own. Either way, people with TP53 abnormalities tend to have shorter periods of disease control and may need different treatment strategies.
Watch and Wait
One of the most surprising things about a CLL diagnosis is that many people don’t need treatment right away. Because the disease progresses slowly and treatments work just as well when started later, doctors often recommend a period of active observation, sometimes called “watch and wait.” This isn’t neglect. It’s a deliberate strategy backed by decades of evidence showing that early treatment in people without symptoms doesn’t improve outcomes.
During this period, you’ll have regular appointments where your medical team monitors your blood counts for trends, checks for new or growing lymph nodes, and asks about symptoms. No single abnormal lab result typically triggers treatment on its own. Instead, your team watches for patterns over time: steadily rising lymphocyte counts, worsening anemia or platelet levels, growing lymph nodes or spleen, or the emergence of B symptoms like significant weight loss or severe fatigue. Some people stay on watch and wait for years, even a decade or more, before needing treatment. Others progress more quickly.
Treatment Options
When treatment does become necessary, the landscape has changed dramatically in the last decade. Traditional chemotherapy has largely been replaced by targeted therapies that attack specific vulnerabilities in CLL cells.
The two main classes of drugs now used are BTK inhibitors and BCL-2 inhibitors. BTK inhibitors block a protein that CLL cells depend on for survival and growth signals. They’re typically taken as a daily pill and are often continued indefinitely as long as they keep working. Several generations of these drugs are now available, with newer versions designed to be more selective and cause fewer side effects.
BCL-2 inhibitors work differently. They target a protein that prevents CLL cells from dying naturally, essentially flipping a switch that allows the cancerous cells to self-destruct. This class of drug is typically given for a fixed duration, often about one year, in combination with an antibody treatment. The idea of a time-limited therapy is appealing to many patients because it offers the possibility of a treatment-free period afterward.
Current guidelines recommend either continuous BTK inhibitor therapy or fixed-duration BCL-2 inhibitor combinations as first-line options. The choice between them depends on several factors, including the genetic profile of the CLL, other health conditions, and patient preference regarding ongoing versus time-limited treatment.
Survival and Long-Term Outlook
The prognosis for CLL has improved substantially over the past several decades. The five-year relative survival rate was 65.1% in 1975 and has climbed to an estimated 88.5% as of 2024. This improvement reflects both better treatments and earlier detection. Many people with early-stage CLL live for decades after diagnosis, and for some, the disease never requires treatment at all. About 4,460 deaths from CLL are estimated in the United States in 2025, making it a disease that, while serious, most people now live with rather than die from.